Download   CLINTON E. CANAL, PH.D. CURRICULUM VITAE

 CLINTON E. CANAL, PH.D.
CURRICULUM VITAE
CONTACT INFORMATION
Research Assistant Professor
Center for Drug Discovery, Department of Pharmaceutical Sciences
211A Mugar Life Sciences Building
Northeastern University
360 Huntington Avenue
Boston, MA 02115
Phone: (617) 373-8736
Email: [email protected]
Web: http://www.linkedin.com/pub/clint-canal/46/427/b39
EDUCATION
08/1994-08/1998
University of Florida
B.S. in Psychology (Biological), Minor in Philosophy
University of Illinois, Urbana-Champaign
08/2000-12/2006
Ph.D. in Neuroscience
Dissertation Title: “Protein synthesis inhibitors impair memory by disrupting release of neurotransmitters
important for memory modulation.”
Committee: Paul E. Gold (adviser), Donna L. Korol, David F. Clayton, Stephanie Ceman
Available: http://www.library.illinois.edu/learn/find/dissertations.html#illinois
University of Illinois, Urbana-Champaign
NIMH Postdoctoral Fellow
Neuroscience Program (Paul E. Gold, adviser)
12/2006-06/2007
Vanderbilt University School of Medicine
NIMH/T32 Postdoctoral Fellow, Training Program in Functional Neurogenomics
Department of Pharmacology (Elaine Sanders-Bush, adviser)
06/2007-08/2009
University of Florida
NIMH and NIDA Postdoctoral Fellow
Department of Medicinal Chemistry, Department of Pharmacology and Therapeutics
(Raymond G. Booth, adviser)
08/2009-09/2012
Northeastern University
Certificate in Health Informatics
09/2014-05/2016 (expected)
PROFESSIONAL EXPERIENCE
Northeastern University
Research Assistant Professor
Center for Drug Discovery, Department of Pharmaceutical Sciences
09/2012-present
RESEARCH SYNOPSIS
My research is dedicated to preclinical, neuropsychiatric drug discovery targeting GPCRs. Currently, I am
focused on targeting specific serotonin receptors for the treatment of core symptoms of autism, schizophrenia,
and related disorders involving alterations in motor behavior, social behavior, cognition, and sensory/perception
(Research Domain Criteria).
EXTRAMURAL RESEARCH SUPPORT
Current
DOD PR141869
Booth/Canal
09/01/2015-02/29/2017
Translation of Novel Serotonin 5-HT7 Agonist Drug Candidates in Rodent Models of Fragile X Syndrome
The primary objective here is to design, synthesize, and discover, in an iterative manner, novel serotonin 7
receptor agonists and assess their effectiveness to correct behavioral and neuroanatomical deficits in an Fmr1
knockout mouse model of fragile X syndrome.
Role: MPI
Total Costs: $309,000
R01 DA030989
Booth
09/01/2010-08/31/2016
Novel Functionally-Selective Serotonin 5-HT2 Drugs for Amphetamines Abuse/Disorders
This project is to advance novel phenylaminotetralin (PAT) analogs as functionally-selective serotonin 5-HT2
receptor-based drug development candidates to treat amphetamine and methamphetamine abuse.
Role: Co-I
Total Costs: $1,802,016
Pending
R21 DA040907
Canal/Murnane
01/01/2016-12/31/2017
Receptor pharmacology and toxicology of second-generation pyrrolidine "bath salt" cathinones
The objective here is twofold: 1) to assess the pharmacological and behavioral toxicological effects of
substituting a pyrrolidine moiety on the cathinone scaffold; 2) to test a novel pharmacotherapeutic strategy for
treating psychostimulant overdose.
Role: MPI
Total Costs: $471,058
R01 MH109330-A1
Booth/Canal
04/01/2016-03/31/2021
Serotonin 5-HT7 and 5-HT1A activation for treating core symptoms of autism spectrum disorder in constructvalid mouse models
This project tests the hypothesis that novel 5-HT7 and 5-HT1A agonists will demonstrate efficacy to reverse
deficits in Cntnap2 deletion mouse model of autism spectrum disorder via mechanisms that enhance central
GABAergic signaling.
Role: MPI
Total Costs: $1,931,250
DOD AR150119/AR150119P1
Booth/Canal
04/01/2016-09/30/2018
Targeting type-7 and related serotonin receptors with a small molecule to treat stereotypy and other core
symptoms of autism spectrum disorders
This project develops novel, dual 5-HT7/5-HT1A agonists to ameliorate autism symptoms in Shank3 deletion
mice.
Role: MPI
Total Costs: $525,300
2|Page
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]
Recently Completed
R01 MH081193
Booth
04/15/2008-04/14/2014
Serotonin 5-HT2C Agonist Ligands with 5-HT2A and 5-HT2B Antagonist Activity
This project utilizes genetically-modified mice (5-HT2C–/–, 5-HT2A–/– “knockout”) to delineate the
mechanism of antipsychotic and anorexient pharmacological activity of novel 5-HT2-targeting ligands.
Role: Co-I
Total Costs: $1,841,323
T32 DA07312
Makriyannis
07/01/1999-09/30/2014
Training Program in Medications Development for Drugs of Abuse
The goal of this program is to train future scientists in the field of drug discovery with a particular emphasis on
therapies related to drugs of abuse.
Role: Training Faculty
Total Costs: $2,396,693
AWARDS AND HONORS
Recipient of Florida Academic Scholarship
1994
Inducted Alpha Lambda Delta Honor Society
1996
Inducted Golden Key National Honor Society
1996
Graduated cum laude with high honors distinction, University of Florida
1998
Recipient of graduate student travel awards, University of Illinois, Dept. of Psychology
Recipient of graduate student travel awards, University of Illinois, Neuroscience Program
2001 & 2002
2003-2006
Elected Attendee, NIH program, National Graduate Student Research Festival
2006
Recipient of C. Ladd Prosser Award (Program's "Highest Honor"), University of Illinois, Neuroscience
2006
Elected attendee, NIDA short course, Genetics and Epigenetics of Addiction
2008
T32 postdoctoral trainee in Functional Neurogenomics, Vanderbilt University School of Medicine
2007-2009
Recipient of young scientist travel award, ASPET Meeting
2008-2009
Postdoctoral scientists award finalist, ASPET Meeting Neuropharmacology Division
2009
Recipient of early career investigator travel award, College on Problems of Drug Dependence
2011
TEACHING SKILLS TRAINING
gradSTEP, Keeping Pace with the Present: Practical Approaches to Teaching Tomorrow's Learners.
“gradSTEP provides workshops and discussions on teaching, learning, and professional development issues
across the disciplines.” Vanderbilt University, 2009.
3rd Annual Thomas A. Hazinski Faculty Development Workshop. “All the TOOLS you need to ENHANCE
your teaching skills, BUILD your portfolio, and PROMOTE your educational scholarship.” Vanderbilt
University, 2009.
Teaching Excellence Workshop. “Designed to provide practical tips and ideas to integrate immediately into
live or online classrooms.” University of Florida, 2012.
3|Page
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]
TEACHING
University of Illinois, Urbana-Champaign
Psychology 210: Brain and Mind (3SH, 9 lecture hours). Fall 2001. ~100 students.
Psychology 210: Brain and Mind (3SH, 12 lecture hours). Spring 2002. ~100 students.
Neuroscience 414: Brain, Learning and Memory (3SH, 6 lecture hours). Fall 2003. ~50 students.
Psychology 211: Techniques of Biological Psychology (4SH, 60 lecture hours). Fall 2004. 12 students.
University of Florida, Gainesville
Pharmacy 6447: Drug Design (3SH, 3 lecture hours). Spring 2012. 10 students.
Northeastern University, Boston
CHME 5699: Quantitative Principles Cell Tissue Engineering (3SH, 2 lecture hours). Spring 2013. 10 students.
PHSC 6222: Chemistry and Biology of Drugs of Abuse (3SH, 3 lecture hours). Fall 2013. ~25 students.
CPE: Professional Development Program for Pharmacists (2 lecture hours). Fall 2014. ~50 pharmacists.
PMCL 6262: Receptor Pharmacology (3SH, 3 lecture hours). Fall 2014. ~25 students.
HLTH 1555: Special Topics in Health Care: Drug Discovery (4SH, 8 lecture hours). Fall 2015. 8 students.
MENTORING
University of Illinois, Urbana-Champaign
Aleksandra Florek, B.S., Molecular and Cellular Biology
Andrew Flesner, B.S., Molecular and Cellular Biology
Anu Adeboje, B.S., Psychology
Coleen See, B.S., Molecular and Cellular Biology
Danuta Dukala, B.S., Molecular and Cellular Biology
Kristen Davis, B.S., Psychology
Renee Haag, Ph.D, Neuroscience program
Sonja Stutz, B.S., Psychology
Vanderbilt University School of Medicine, Nashville
Brett Begley, B.S., Pharmacology
Kontip Mahautmr, M.S., Pharmacology
Erin Watt, B.S., Pharmacology
University of Florida, Gainesville
Daniel Felsing, B.S., Chemistry
Krishnakanth Kondabolu, Ph.D., Medicinal Chemistry
Sean Travers, Ph.D., Medicinal Chemistry
4|Page
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]
Northeastern University, Boston
Charles Perry, Ph.D., Medicinal Chemistry (expected 2018)
Daniel Felsing, Ph.D., Medicinal Chemistry (expected 2016)
Jimit Raghav, Ph.D., Pharmaceutical Sciences (expected 2018)
Laura Purcell, M.S., Pharmaceutical Sciences (expected 2016)
Ngan Tran, M.S., Pharmaceutical Sciences
Wanying Zhu, M.S., Pharmaceutical Sciences
Yajun Lin, M.S., Pharmaceutical Sciences (expected 2016)
Yan Zhou, M.S., Pharmaceutical Sciences (expected 2016)
Yue Liu, Ph.D., Postdoctoral Trainee
Ph.D. Committees
Charles Perry, Northeastern University, Department of Pharmaceutical Sciences
Daniel Felsing, University of Florida, Department of Medicinal Chemistry
Jimit Raghav, Northeastern University, Department of Pharmaceutical Sciences
Murai Han, Northeastern University, Department of Pharmaceutical Sciences
Qi Ye, Northeastern University, Department of Pharmaceutical Sciences
SERVICE
Ad Hoc Reviewer for Biomedical Journals
ACS Chemical Neuroscience
ACS Journal of Medicinal Chemistry
ACS Medicinal Chemistry Letters
Behavioral Pharmacology
Behavioural Brain Research
BMC Neuroscience
Czech Journal of Animal Science
Drugs of Today—Prous Thomson Reuters
European Journal of Medicinal Chemistry
Frontiers in—Neurology, Neuroscience, Pharmacology and Psychiatry
Journal of Neurochemistry
Learning & Memory
Medicinal Chemistry Communications
Neurobiology of Learning and Memory
Neuropharmacology
Neurotoxicity Research
Pharmacogenomics and Personalized Medicine
Pharmacology Biochemistry and Behavior
Physiology & Behavior
5|Page
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]
2004-present
University Service
University library advisory committee, University of Illinois, Urbana-Champaign
Assistant to Neuroscience program coordinator, University of Illinois, Urbana-Champaign
Bouvé College of Health Sciences web committee, Northeastern University
Early Career Reviewer
2014-present
Center for Scientific Review, NIH
Editorial Board
2015-present
Review Editor, Editorial Board of Neuropharmacology, a specialty of Frontiers in—Neurology, Neuroscience,
Pharmacology and Psychiatry
PUBLICATIONS
1. Canal, C.E., McNay, E.C., & Gold, P.E. (2005). Increases in extracellular fluid glucose levels in the rat
hippocampus following an anesthetic dose of pentobarbital or ketamine-xylazine: an in vivo microdialysis
study. Physiology & Behavior, 84, 245-250. PMID: 15708776
2. Canal, C.E., Stutz, S.J., & Gold, P.E. (2005). Glucose injections into the dorsal hippocampus or dorsolateral
striatum of rats prior to T-maze training: modulation of learning rates and strategy selective. Learning &
Memory, 12, 367-374. PMID: 16027177; PMCID: PMC1183254.
3. McNay, E.C., Canal, C.E., & Gold, P.E. (2006). Modulation of memory with septal injections of morphine
and glucose: effects on extracellular glucose levels in the hippocampus. Physiology & Behavior, 87, 298303. PMID: 16343563
4. Canal, C.E., & Gold, P.E. (2007). Different temporal profiles of amnesia after intra-hippocampus and
intra-amygdala anisomycin infusions. Behavioral Neuroscience, 121, 732-741. PMID: 17663598
5. Canal, C.E., Chang, Q., & Gold, P.E. (2007). Amnesia produced by altered release of neurotransmitters
after intra-amygdala injections of a protein synthesis inhibitor. Proceedings of the National Academy of
Sciences of the United States of America, 104, 12500-12505. PMID: 17640910; PMCID: PMC1941498.
6. Canal, C.E., Chang, Q., & Gold, P.E. (2008). Intra-amygdala injections of CREB antisense impair
inhibitory avoidance memory: role of norepinephrine and acetylcholine. Learning & Memory, 15, 677-686.
PMID: 18772255; PMCID: PMC2632786.
7. Canal, C.E., Mahautmr, K.C., Cao, C., Sanders-Bush, E., Airey, D.C. (2009). RNA editing of the serotonin
2C receptor and expression of Gαq protein: genetic mouse models do not support a role for regulation or
compensation. Journal of Neurochemistry, 108(5), 1136-1142. PMID: 19154337; PMCID: PMC2742694.
8. Olaghere da Silva, U.B., Morabito, M.V., Canal, C.E., Airey, D.C., Emeson, R.B., Sanders-Bush, E.
(2010). Impact of RNA editing on functions of the serotonin 2C receptor in vivo. Frontiers in
Neuropharmacology, volume 4, article 26. PMID: 20582266; PMCID: PMC2858556.
9. Canal, C.E., Olaghere da Silva, U.B., Gresch, P.J., Watt, E.E., Sanders-Bush, E., Airey, D.C. (2010). The
serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine
hallucinogen. Psychopharmacology, 209(2), 163-174. PMID: 20165943; PMCID: PMC2868321.
10. Sadowski, R.N., Canal, C.E., Gold, P.E. (2011). Lidocaine attenuates anisomycin-induced amnesia and
release of norepinephrine in the amygdala. Neurobiology of Learning and Memory, 96, 136-142. PMID:
21453778; PMCID: PMC3148321.
11. Cordova-Sintjago, T.C., Villa, N.Y., Canal, C.E., Booth, R.G. (2011). Human serotonin 5-HT2C G proteincoupled receptor homology model from the β2 adrenergic receptor structure: ligand docking and
6|Page
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]
mutagenesis studies. International Journal of Quantum Chemistry, 112(1), 140-149. PMID: 24244046;
PMCID: PMC3826658.
12. Canal, C.E., Cordova-Sintjago, T.C., Villa, N.Y., Fang, L., Booth, R.G. (2011). Drug discovery targeting
human 5-HT2C receptors: Residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen
bond formation. European Journal of Pharmacology, 673, 1-12. PMID: 22020288; PMCID:
PMC3224194.
13. Canal, C.E., Morgan, D. (2012). Head-twitch response in rodents induced by the hallucinogen 2,5dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its current
utility as a model. Drug Testing and Analysis, 4(7-8), 556-576. PMID: 22517680; PMCID: PMC3722587.
14. Cordova-Sintjago, T.C., Sakhuja, R., Kondabolu, K., Canal, C.E., Booth, R.G. (2012) Molecular
determinants for ligand binding at serotonin 5-HT2A and 5-HT2C GPCRs: Affinity results analyzed by
molecular modeling and ligand docking studies. International Journal of Quantum Chemistry, 112, 38073814. PMID: 23913978; PMCID: PMC3729958.
15. Morgan, D., Canal, C.E., Kondabolu, K., Sakhuja, R., Robertson, K.L., Rowland, N.E., Booth, R.G (2012).
A novel serotonin-2 (5-HT2) modulator as a candidate drug to treat impulsive behavioral disorders and
psychoses without weight gain as a side effect. Neuropsychopharmacology, 38, S104-105. 0893-133X/12
16. Canal, C.E., Morgan, D., Booth, R.G. (2013). Support for 5-HT2C receptor functional selectivity in vivo
utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine
elicited head-twitch response model. Neuropharmacology, 70, 112-121. PMID: 23353901; PMCID:
PMC3754837.
17. Canal, C.E., Cordova-Sintjago, T., Liu, Y., Kim, M.S., Morgan, D., Booth, R.G. (2013). Molecular
pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human
serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin
ligands. Journal of Pharmacology and Experimental Therapeutics, 347(3), 705-716. PMID: 24080681;
PMCID: PMC3836315.
18. Canal, C.E., Morgan, D., Kondabolu, K., Robertson, K., Rowland, N.E., Booth, R.G. (2014). A novel
aminotetralin-type serotonin (5-HT)2C receptor-specific agonist and 5-HT2A competitive antagonist/5HT2B inverse agonist with preclinical efficacy for psychoses. Journal of Pharmacology and Experimental
Therapeutics, 349, 1-9 PMID: 24563531; PMCID: PMC3989798.
19. Sakhuja, R., Kondabolu, K., Travers, S., Cordova-Sintjago, T., Sun, Z., Vincek, A.S., Kim, M.S., Fang, L.,
Abboud, K.A., Canal, C.E., Booth, R.G. (2015). Novel 4-substituted-N,N-dimethyl-tetrahydronaphthalen2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G
protein-coupled receptors. Bioorganic Medicinal Chemistry, 23(7), 1588-1600. PMID: 25703249; PMCID:
PMC4363177.
20. Morgan, D., Canal, C.E., Orza, P.C., Rose, J.L., Kim, M.S., Booth, R.G. (2015). A novel 5-HT2C-specific
agonist/5-HT2A-2B antagonist attenuates psychomotor behaviors induced by methamphetamine,
oxycodone, and their combination. Drug & Alcohol Dependence 146, e46,
doi.org/10.1016/j.drugalcdep.2014.09.497
21. Canal, C.E., Felsing, D., Liu, Y., Zhu, W., Wood, J., Perry, C.K., Vemula, R., Booth, R.G. (2015). An
orally-active phenylaminotetralin-chemotype serotonin 5-HT7 and 5-HT1A receptor partial agonist that
corrects motor stereotypy in mouse models. ACS Chemical Neuroscience, 6, 1259-1270 PMID: 26011730
7|Page
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]
INVITED LECTURES
"Head-twitch response in rodents induced by serotonin-like hallucinogens: role of serotonin 2A and serotonin
2C receptors." M.A.P.S. Conference, Psychedelic Science in the 21st Century (San Jose, CA), April 16, 2010.
“Preclinical Development of a Specific Serotonin 2C Receptor Agonist for Psychoses.” Pharmacology
Colloquium, Department of Pharmaceutical Sciences, Northeastern University (Boston, MA), October 18, 2012.
“Preclinical Development of a Serotonin 2C Receptor Specific Agonist for Psychostimulant-Induced
Psychoses.” Current Trends in Drug Abuse Research, 11th Annual Symposium, Northeastern University
(Boston, MA), May 17, 2013.
“Development of Serotonin 2 Compounds for Neuropsychiatric Disorders: Focus on Treating Impulsivity, a
Common Endophenotype.” Pharmaceutical Sciences Research Showcase, Northeastern University (Boston,
MA), May 24, 2013.
“Developing Novel Ligands Targeting Serotonin 5-HT7 Receptors: 5-HT7 Agonists Attenuate
Psychostimulant-Induced Behaviors.” Scientific Advisory Board Meeting, Center for Drug Discovery,
Northeastern University (Boston, MA), December 19, 2013.
“The Unusual Suspects: Central 5-HT2 and 5-HT7 Receptors as Targets for Psychiatric Disorders: Preclinical
Evidence from Novel Aminotetralin Ligands.” College of Pharmacy, Mercer University (Atlanta, GA), March
27, 2014.
“The Neurobiology of Psychedelic Drugs: What We Know and What We May Never Know.” Psymposium
Conference, University of Massachusetts (Amherst, MA), April 13, 2014.
“Development of Novel Drugs Targeting Serotonin Receptors for Cognitive Dysfunction.” Pharmaceutical
Sciences Research Showcase, Northeastern University (Boston, MA), May 16, 2014.
MEETING ABSTRACTS AND PRESENTATIONS
Canal, C.E., Stutz, S.J., & Gold, P.E. Impairment of learning in a T-maze following intrastriatal but not
intrahippocampal glucose injections: no differences in learning strategy. Society for Neuroscience, 31st Annual
Meeting (San Diego, CA), 2001.
Canal, C.E., McNay, E.C., & Gold, P.E. Effects of intraseptal morphine injections on hippocampal
extracellular glucose levels and memory. Society for Neuroscience, 32nd Annual Meeting (Orlando, FL), 2002.
Canal, C.E., McNay, E.C., & Gold, P.E. Increases in glucose levels in hippocampal ECF and blood during
ketamine or pentobarbital anesthesia. Society for Neuroscience, 33rd Annual Meeting (New Orleans, LA),
2003.
Canal, C.E. & Gold, P.E. Amygdala CREB antisense impairs 48 hr memory of inhibitory avoidance and spatial
T-maze training yet dorsal hippocampus CREB antisense impairs memory only of spatial T-maze training.
Society for Neuroscience, 34th Annual Meeting (San Diego, CA), 2004.
Chang, Q., Canal, C.E., & Gold, P.E. Amygdala CREB antisense decreases training-related norepinephrine
release and impairs memory of inhibitory avoidance. Society for Neuroscience, 35th Annual Meeting
(Washington, D.C.), 2005.
Canal, C.E. & Gold, P.E. Amygdala anisomycin impairs short- and long-term memory of inhibitory avoidance.
Society for Neuroscience, 35th Annual Meeting (Washington, D.C.), 2005.
Canal, C.E. & Gold, P.E. Effects of posttraining amygdala noradrenergic stimulation on amygdala CREB
antisense-induced memory impairment. Society for Neuroscience, 36th Annual Meeting (Atlanta, GA), 2006.
Sadowski, R.N., Canal, C.E., Chang, Q., Qi, Z., & Gold, P.E. Amnestic doses of anisomycin injected into the
amygdala produce large changes in the release of norepinephrine, dopamine, & serotonin. Society for
Neuroscience, 37th Annual Meeting (San Diego, CA), 2007.
8|Page
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]
Canal, C.E., Mahautmr, K.C., Jacobs, M.M., Sanders-Bush, E., Airey, D.C. No relationship found between
RNA editing of the serotonin 2c receptor and expression of Gαq protein. Experimental Biology, 2008, ASPET
Centennial Meeting (San Diego, CA), 2008.
Canal, C.E., Watt, E.E., Sanders-Bush, E. Ex vivo and in vivo changes in function of the serotonin 2C receptor
due to RNA editing. Experimental Biology (New Orleans, LA), 2009.
Gold, P.E., Sadowski, R.N., Canal, C.E. Lidocaine attenuates both anisomycin-induced impairments of
memory and associated large increases in norepinephrine release in the amygdala. Society for Neuroscience,
39th Annual Meeting (Chicago, IL), 2009.
Canal, C.E., Da Silva, U.O., Gresch, P.J., Watt, E.E., Seitz, K.P., Sanders- Bush, E., Airey, D.C.
Hallucinogenic behavioral response in mice is potently modulated by the serotonin 2C receptor. Society for
Neuroscience, 39th Annual Meeting (Chicago, IL), 2009.
Cordova-Sintjago, T., Villa, N.Y., Canal, C.E., Booth, R.G. 5-HT2C homology model from the β2-adrenergic
receptor and mutagenesis studies: the role of S3.36 and Y7.43. Sanibel Symposium Annual Meeting (St. Simon
Island, GA), 2011.
Canal, C.E., Morgan, D., Booth, R.G. A novel, functionally-selective serotonin 2 receptor ligand blocks
putative psychotomimetic effects of (±)-2,5-dimethoxy-4-iodoamphetamine in mice. The College on Problems
of Drug Dependence, Annual Meeting (Hollywood, FL), 2011.
Canal, C.E., Morgan, D, Booth, R.G. Development of serotonin 5-HT2C agonists with 5-HT2A/2B antagonist
activity as antipsychotics without weight gain liability. Proceedings of the 47th International Conference on
Medicinal Chemistry (Lyon, France), 2011.
Kasper, J., MacFadyen, K., Tikamdas, R., Kim, M.S., Canal, C.E., Booth, R.G., Peris, J. A novel serotonin 5HT2C agonist/5-HT2A/2B antagonist selectively decreases ethanol self-administration and inhibits the alcohol
deprivation effect. Annual Meeting of the Research Society on Alcoholism (San Francisco, CA), 2012.
Cordova-Sintjago, T., Sakhuja, R., Kondabolu, K., Villa, N.Y., Canal, C.E., Booth, R.G. Molecular
determinants for binding and function at serotonin 5-HT2A and 5-HT2C GPCRs: Ligand Docking, Molecular
Dynamic and QM Studies. 52nd Sanibel Symposium (St. Simon Island, GA), 2012.
Morgan, D., Canal, C.E., Kondabolu, K., Sakhuja, R., Robertson, K.L., Rowland, N.E., Booth, R.G. A novel
serotonin-2 (5-HT2) modulator as a candidate drug to treat impulsive behavioral disorders and psychoses
without weight gain as a side effect. American College of Neuropsychopharmacology annual meeting
(Hollywood, FL), 2012.
Villa, N.Y., Cordova-Sintjago, T.C., Canal, C.E., Fang, Li-J., Booth, R.G. Serotonin 5-HT2C residues W6.48,
F6.51, and F6.52 are involved in functionally-selective ligand binding and signaling efficacy. Society for
Neuroscience, 42nd Annual Meeting (New Orleans, LA), 2012.
Morgan, D., Kondabolu, K., Ajufo, C., Orza, P., Nwokolo, J., Sakhuja, R., Robertson, K.L., Felsing, D., Canal,
C.E., Rowland, N.E., Booth, R.G. A novel 5-HT2 modulator as a potential antipsychotic medication. The
College on the Problems of Drug Dependence, Annual Meeting (San Diego, CA), 2013.
Canal, C.E., Morgan, D., Kondabolu, K., Sakhuja, R., Felsing, D., Robertson, K., Rowland, N., Booth, R.G. A
new potent and specific 5-HT2C receptor agonist with preclinical anti-psychotic and anti-obesity properties.
Experimental Biology (Boston, MA), 2013.
Booth, R.G., Morgan, D., Rowland, N., Kondabolu, K., Canal, C.E., Sakhuja, R. Translation of monovalent
serotonin 5-HT2A antagonists/5-HT2C agonist drug candidates for schizophrenia. International Conference on
Medicinal Chemistry, Drug Discovery and Selection (Nice, France), 2013.
Booth, R.G., Morgan, D., Rowland, N., Kondabolu, K., Sakhuja, R., Canal, C.E. Novel orally-active 5-HT2C
agonists with 5-HT2A/2B antagonist activity demonstrate efficacy to treat psychoses without weight gain. 31st
Camerino-Cyprus-Noordwijkerhout Symposium “Receptor Chemistry Skyline” (Camerino, Italy), 2013.
9|Page
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]
Morgan, D., Canal, C.E., Kondabolu, K., Kim, M.S., Robertson, K., Rowland, N., Sizemore, G.N., Booth, R.G.
Development of a novel class of antipsychotics: Multifunctional PAT compounds (5-HT2A antagonists/5HT2C agonists) ameliorate the positive and cognitive disrupting symptoms associated with psychosis.
American College of Neuropsychopharmacology annual meeting, 2013.
Cordova-Sintjago, T., Liu, Y., Canal, C.E., Booth, R.G. Molecular interactions of agonist and inverse agonist
ligands at serotonin 5-HT2C G protein-coupled receptors: docking, molecular Dynamics, and experimental
Studies. 54th Sanibel Symposium (St. Simon Island, Georgia), 2014.
Felsing, D., Canal, C.E., Booth, R.G. Ligand induced desensitization of serotonin 5-HT2C GPCRs. RISE:
Research, Innovation, and Scholarship Expo, Northeastern University (Boston, MA), 2014.
Liu, Y., Canal, C.E., Booth, R.G. Molecular determinants governing activation versus inactivation of serotonin
(5-HT)2C receptors by 4-phenyl-2-dimethylaminotetralin analogs. RISE: Research, Innovation, and Scholarship
Expo, Northeastern University (Boston, MA), 2014.
Canal, C.E., Felsing, D.E., Perry, C.K., Liu, Y., Booth, R.G. Preclinical development of a serotonin (5-HT)7
and 5-HT1A partial agonist for autism. 6th Cisbio HTRF symposium (Brewster, MA), 2015.
PROFESSIONAL AFFILIATIONS
American Society for Pharmacology and Experimental Therapeutics
Nu Rho Psi
Society for Neuroscience
CONSULTING ACTIVITY
Seropeutics, LLC, Boston, MA
10 | P a g e
May 2015-present
Clinton E. Canal, Ph.D. (617) 373-8736 [email protected]